Drug Trial Radar · NCT03101930
Cardiovascular Effects of GLP-1 Receptor Activation
Last checked: Nov 19, 2026Latest source record: Oct 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
329
Actual
Start
May 1, 2017
Primary completion
Jun 24, 2021
Study completion Jun 24, 2021
Sponsor
- Lead sponsor
- Vanderbilt University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Heart Association
- First posted
- Apr 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual factors that modulate GLP1R sensitivity can modify the effect of these analogues on cardiovascular risk.
Conditions
- Obesity
- PreDiabetes
Interventions
LiraglutideDrug
subcutaneous liraglutide daily
SitagliptinDrug
oral sitagliptin daily
hypocaloric dietOther
Reduced calorie intake to achieve weight loss.
PlacebosDrug
Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
Exendin (9-39)Drug
All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Flow-mediated DilationTime frame: Baseline to 2 and 14 weeks
- Urine Albumin-to-creatinine RatioTime frame: Baseline to 13 weeks
- Change in Plasminogen Activator Inhibitor-1Time frame: Baseline to 2 and 14 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University Medical Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.